GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vistagen Therapeutics Inc (NAS:VTGN) » Definitions » Total Assets

VTGN (Vistagen Therapeutics) Total Assets : $84.34 Mil (As of Mar. 2025)


View and export this data going back to 2009. Start your Free Trial

What is Vistagen Therapeutics Total Assets?

Vistagen Therapeutics's Total Assets for the quarter that ended in Mar. 2025 was $84.34 Mil.

During the past 12 months, Vistagen Therapeutics's average Total Assets Growth Rate was -14.00% per year. During the past 3 years, the average Total Assets Growth Rate was -16.00% per year. During the past 5 years, the average Total Assets Growth Rate was -4.20% per year. During the past 10 years, the average Total Assets Growth Rate was 36.20% per year.

During the past 13 years, Vistagen Therapeutics's highest 3-Year average Total Assets Growth Rate was 539.10%. The lowest was -16.00%. And the median was 38.10%.

Total Assets is connected with ROA %. Vistagen Therapeutics's annualized ROA % for the quarter that ended in Mar. 2025 was -61.75%. Total Assets is also linked to Revenue through Asset Turnover. Vistagen Therapeutics's Asset Turnover for the quarter that ended in Mar. 2025 was -0.00.


Vistagen Therapeutics Total Assets Historical Data

The historical data trend for Vistagen Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vistagen Therapeutics Total Assets Chart

Vistagen Therapeutics Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 108.28 74.64 21.09 123.65 84.34

Vistagen Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 123.65 113.55 102.50 92.31 84.34

Vistagen Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Vistagen Therapeutics's Total Assets for the fiscal year that ended in Mar. 2025 is calculated as

Total Assets=Total Equity (A: Mar. 2025 )+Total Liabilities (A: Mar. 2025 )
=70.39+13.951
=84.34

Vistagen Therapeutics's Total Assets for the quarter that ended in Mar. 2025 is calculated as

Total Assets=Total Equity (Q: Mar. 2025 )+Total Liabilities (Q: Mar. 2025 )
=70.39+13.951
=84.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vistagen Therapeutics  (NAS:VTGN) Total Assets Explanation

Total Assets is connected with ROA %.

Vistagen Therapeutics's annualized ROA % for the quarter that ended in Mar. 2025 is

ROA %=Net Income (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=-54.54/( (92.307+84.341)/ 2 )
=-54.54/88.324
=-61.75 %

Note: The Net Income data used here is four times the quarterly (Mar. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Vistagen Therapeutics's Asset Turnover for the quarter that ended in Mar. 2025 is

Asset Turnover
=Revenue (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=-0.015/( (92.307+84.341)/ 2 )
=-0.015/88.324
=-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Vistagen Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Vistagen Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Vistagen Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
343 Allerton Avenue, South San Francisco, CA, USA, 94080
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
Executives
Joshua S. Prince officer: Chief Operating Officer C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Cynthia Lynn Anderson officer: CHIEF FINANCIAL OFFICER C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Commodore Capital Lp 10 percent owner 444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Jerry B Gin director 343 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Reid G. Adler officer: CHIEF LEGAL OFFICER C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94090
Shawn Singh director, officer: CHIEF EXECUTIVE OFFICER C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Venrock Healthcare Capital Partners Ii, L.p. 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Ii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Eg, Llc 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Healthcare Capital Partners Eg, L.p. 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Vhcp Co-investment Holdings Iii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Bong Y Koh 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Co-investment Holdings Ii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Nimish P Shah 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018
Venrock Healthcare Capital Partners Iii, L.p. 10 percent owner 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036